Cargando…

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes

OBJECTIVE: To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 24-week open-label, multicenter study, 113 patients were randomly assigne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riddle, Matthew, Pencek, Richard, Charenkavanich, Supoat, Lutz, Karen, Wilhelm, Ken, Porter, Lisa
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732154/ https://www.ncbi.nlm.nih.gov/pubmed/19502544 http://dx.doi.org/10.2337/dc09-0395

Ejemplares similares

A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
por: Johnson, Mary L., et al.
Publicado: (2022)

Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis
por: Bonafede, Machaon M, et al.
Publicado: (2011)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015)

Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
por: Pullman, John, et al.
Publicado: (2006)

Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
por: Evans, Marc, et al.
Publicado: (2019)

Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
por: Maikawa, Caitlin L., et al.
Publicado: (2021)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
por: Matsuhisa, M., et al.
Publicado: (2016)

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
por: Jain, S M, et al.
Publicado: (2010)

Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch
por: Peyrot, Mark, et al.
Publicado: (2018)

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes
por: Paczkowski, R., et al.
Publicado: (2023)

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances meal-time glucagon suppression in diabetic pigs
por: Maikawa, Caitlin L., et al.
Publicado: (2020)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study
por: Sheldon, Eric A., et al.
Publicado: (2012)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study
por: Bolli, Geremia B., et al.
Publicado: (2009)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Daily injection of melatonin inhibits insulin resistance induced by chronic mealtime shift
por: Park, Jihyun, et al.
Publicado: (2022)

Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
por: Lane, Wendy, et al.
Publicado: (2021)

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
por: Davies, M J, et al.
Publicado: (2014)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
por: Le Floch, Jean-Pierre, et al.
Publicado: (2009)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Abstract 21: The burden of mealtime insulin dosing in adults and children with type 1 diabetes
por: Revanna, Manjunatha, et al.
Publicado: (2022)

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
por: Qiao, Yong-Chao, et al.
Publicado: (2017)

Improving the Estimation of Mealtime Insulin Dose in Adults With Type 1 Diabetes: The Normal Insulin Demand for Dose Adjustment (NIDDA) study
por: Bao, Jiansong, et al.
Publicado: (2011)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
por: Bergenstal, Richard M., et al.
Publicado: (2008)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
por: Rodbard, Helena W, et al.
Publicado: (2018)

Mealtime insulin BOLUS score increases prior to clinic visits in youth with type 1 diabetes
por: McConville, Andrew, et al.
Publicado: (2020)

Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles
por: Emami, Jaber, et al.
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cvsq37a50j83ujhq8ts1ofpvpk